<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01186913</url>
  </required_header>
  <id_info>
    <org_study_id>DAIT RDCRN PIDTC-6901</org_study_id>
    <nct_id>NCT01186913</nct_id>
    <nct_alias>NCT02108067</nct_alias>
  </id_info>
  <brief_title>Natural History Study of SCID Disorders</brief_title>
  <official_title>A Prospective Natural History Study of Diagnosis, Treatment and Outcomes of Children With SCID Disorders (RDCRN PIDTC-6901)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Office of Rare Diseases (ORD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Individuals with Primary Immune Deficiency (PID) may develop severe, life-threatening
      infections as a result of inherited defects in the genes that normally instruct blood-forming
      cells to develop and to fight infections. PID diseases include Severe Combined Immune
      Deficiency (SCID), leaky SCID, Omenn syndrome (OS), and Reticular Dysgenesis (RD). PIDs may
      be treated by transplantation of bone marrow stem cells from a healthy person or, in some
      cases, by enzyme replacement or by gene therapy. Patients with SCID were among the first to
      receive bone marrow stem cell (also called hematopoietic cells) transplantation (HCT) more
      than 40 years ago, and HCT is the standard treatment today for this group of diseases. Since
      PID diseases are rare, there are not enough patients at any single center to determine the
      full range of causes, natural history, or best methods of treatment. For this research study
      many PID centers across North America have organized into the Primary Immune Deficiency
      Treatment Consortium (PIDTC) to pool their experience and study PIDs together. The overall
      goal of this study is the prospective evaluation of children with SCID and related disorders
      who are treated under a variety of protocols at participating institutions. The study aims to
      identify variables contributing to the best outcomes for HCT.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study follows participants with SCID prospectively, meaning the study enrolls
      participants where there is a plan to receive a blood and marrow transplant, enzyme therapy,
      or gene therapy in the future. Participants are then followed according to a schedule set out
      by the study protocol after the procedure. There are no experimental therapies on this study.

      The study plans to enroll over 200 participants with SCID. By studying new participants
      undergoing treatment for SCID, the goal is to learn more about: (1) outcomes from the
      treatment of SCID in the modern era of medicine (2) what factors lead to the best long-term
      outcomes, such as best donor, conditioning regimen, timing of transplant, etc., and (3) what
      impact newborn screening and the early diagnosis of SCID has had on the long-term outcomes
      following BMT or gene therapy. Information is also being gathered on how and when the immune
      system recovers after BMT, quality of life for long-term survivors, and about whether
      children develop normally after treatment.

      This natural history study is the largest coordinated prospective study of participants with
      SCID ever performed. Information that we will learn, both now and in the future, will help
      doctors and other health professionals to better treat children with SCID.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2010</start_date>
  <completion_date type="Anticipated">August 2019</completion_date>
  <primary_completion_date type="Anticipated">August 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival following HCT</measure>
    <time_frame>4 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Full T cell reconstitution</measure>
    <time_frame>6 months post HCT</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Full T cell reconstitution</measure>
    <time_frame>12 months post HCT</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Full T cell reconstitution</measure>
    <time_frame>24 months post HCT</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Full B cell reconstitution</measure>
    <time_frame>12 months post HCT</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Full B cell reconstitution</measure>
    <time_frame>24 months post HCT</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Engraftment</measure>
    <time_frame>100 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Engraftment</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Engraftment</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Engraftment</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infections</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Growth and Nutrition</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Graft versus Host Disease</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of autoimmunity requiring treatment</measure>
    <time_frame>Throughout the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurodevelopment/Neurocognition</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Other complications of HCT needing treatment</measure>
    <time_frame>Throughout the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">209</enrollment>
  <condition>SCID</condition>
  <condition>Leaky SCID</condition>
  <condition>Omenn Syndrome</condition>
  <condition>Reticular Dysgenesis</condition>
  <condition>ADA Deficiency</condition>
  <condition>XSCID</condition>
  <arm_group>
    <arm_group_label>Classic SCID (Stratum A)</arm_group_label>
    <description>Patients with classic SCID after allogeneic hematopoietic stem cell transplantation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Leaky SCID, Omenn syndrome, or RS (Stratum B)</arm_group_label>
    <description>Patients with leaky SCID, Omenn syndrome, or Reticular Dysgenesis (RS) after allogeneic hematopoietic stem cell transplantation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ADA Deficiency or XSCID treated with PEG-ADA (Stratum C)</arm_group_label>
    <description>Patients with ADA Deficiency or XSCID who are treated with PEG-ADA (patients with ADA Deficiency) or patients who are treated with gene therapy (ADA Deficiency or XSCID)</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Peripheral blood samples, tissue, and bone marrow samples collected during participation in
      this study.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with diagnosis of SCID or SCID variants treated at Consortium Centers from
        1968-2010
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Stratum A, Classic SCID.

        Subjects who meet the following inclusion criteria and the intention is to treat with
        allogeneic hematopoietic cell transplant (HCT) are eligible for enrollment into Stratum A
        (Classic SCID):

          -  Absence or very low number (&lt;300 /ÂµL) of CD3+T cells, AND

          -  No or very low (&lt;10% of lower limit of normal) T cell function (as measured by
             response to phytohemagglutinin (HLA) OR

               -  T cells of maternal origin present.

               -  Stratum B, Leaky SCID, Omenn Syndrome, Reticular Dysgenesis.

        Subjects who meet the following criteria and the intention is to treat with HCT are
        eligible for enrollment into Stratum B:

        Leaky SCID:

          -  Maternal lymphocytes not detected;

          -  AND either one or both of the following with rule-out of MHC Class I and II non-
             expression by flow cytometry (or histology):

               -  &lt;30% of lower limit of normal T cell function (as measured by response to PHA),
                  OR

               -  Absent or &lt;10% of lower limit of normal proliferative responses to candida and
                  tetanus toxoid antigens (post vaccination or exposure), with expression of HLA by
                  flow/serology.

          -  AND either one or both of the following:

               -  â¥80% of CD3+ or CD4+ T cells are CD45RO+ (at â¤2 years of age), OR

               -  Genetic abnormality for SCID.

          -  AND does not meet criteria for Omenn Syndrome.

        Omenn Syndrome:

          -  Generalized skin rash;

          -  Maternal lymphocytes not detected;

             --Note: If maternal engraftment was not assessed and ruled out, the patient is not
             eligible as Omenn Syndrome.

          -  â¥80% of CD3+ or CD4+ T cells are CD45RO+ ( â¤ 2 years of age)

          -  Absent or low (&lt; 30% lower limit of normal) T cell proliferation to antigens

        NOTE: If proliferation to antigen was not performed, but at least 4 of the following 8
        supportive criteria, at least one of which must be among those marked with an asterisk (*)
        below are present, the subject is eligible as Omenn Syndrome:

          -  Hepatomegaly

          -  Splenomegaly

          -  Lymphadenopathy

          -  Elevated IgE

          -  Elevated absolute eosinophil count

          -  *Oligoclonal T cells measured by CDR3 length or flow cytometry

          -  *Proliferation to PHA is reduced &lt; 30% of lower limit of normal or SI &lt; 20

          -  *Mutation to SCID causing gene.

        Reticular Dysgenesis:

          -  &lt;300/ÂµL number of T cells (CD3 &lt; 300 / ÂµL);

          -  None or &lt;10% lower limit of normal PHA proliferation;

          -  Severe neutropenia (absolute neutrophil count &lt; 200 /ÂµL); AND

          -  One or more of the following:

               -  Sensori-neural deafness OR

               -  Deficiency of marrow granulopoiesis on bone marrow examination OR

               -  A pathogenic mutation in the adenylate kinase 2 (AK2) gene identified.

        Stratum C, SCID with Non-HCT Treatments. Subjects who meet the following criteria and the
        intention is to treat with PEG-ADA or gene transfer with autologous modified cells are
        eligible for enrollment into Stratum C:

          -  ADA Deficient SCID with intention to treat with PEG-ADA;

          -  ADA Deficient SCID with intention to treat with gene transfer; or

          -  X-linked SCID with intention to treat with gene transfer. Note: For subjects with
             presumed ADA SCID, T cell studies MUST be obtained prior to enzyme replacement therapy
             with PEG-ADA ERT or blood transfusion.

        Exclusion Criteria:

        -Subjects who meet any of the following exclusion criteria are disqualified from enrollment
        in Strata A, B, or C of the study:

          -  Presence of an HIV infection (by PCR) or other cause of secondary immunodeficiency;

          -  Presence of DiGeorge syndrome;

          -  MHC Class I and MHC Class II antigen deficiency; and

          -  Metabolic conditions that imitate SCID or related disorders such as folate transporter
             deficiency, severe zinc deficiency, transcobalamin deficiency.

          -  The majority of subjects with deficiency defects such as nucleoside phosphorylase
             ,ZAP70, CD40 ligand , NEMO, XLP, cartilage hair hypoplasia or ataxia telangiectasia.

               -  Case by case exceptions for Stratum B for subject(s) with one of these deficiency
                  defects, as determined by the PID SCID Review Panel.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chris Dvorak, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UCSF Children's Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Morton J. Cowan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UCSF Children's Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fredrick Goldman, MD</last_name>
      <phone>205-939-5855</phone>
      <email>fgoldman@peds.uab.edu</email>
    </contact>
    <investigator>
      <last_name>Fredrick Goldman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Phoenix Children's Hospital</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Holly Miller, MD</last_name>
      <phone>602-933-0920</phone>
      <email>hmiller2@phoenixchildrens.com</email>
    </contact>
    <investigator>
      <last_name>Holly Miller, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Renna Killen, RN</last_name>
      <phone>323-361-2217</phone>
      <email>rkillen@chla.usc.edu</email>
    </contact>
    <investigator>
      <last_name>Neena Kapoor, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California, Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095-1752</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Theodore Moore, MD</last_name>
      <phone>310-825-6708</phone>
      <email>TBMoore@mednet.ucla.edu</email>
    </contact>
    <investigator>
      <last_name>Theodore Moore, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California San Francisco Children's Hospital</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143-1278</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elizabeth Dunn, MA</last_name>
      <phone>415-502-0203</phone>
      <email>Elizabeth.Dunn@ucsf.edu</email>
    </contact>
    <investigator>
      <last_name>Morton Cowan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katja Weinacht, MD</last_name>
      <phone>617-919-8775</phone>
      <email>kgw1@stanford.edu</email>
    </contact>
    <investigator>
      <last_name>Katja Weinacht, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Denver</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80220</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Craddock, MD</last_name>
      <phone>720-777-3328</phone>
      <email>John.Craddock@childrenscolorado.org</email>
    </contact>
    <investigator>
      <last_name>John Craddock, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Alfred I. duPont Hospital for Children/Nemours</name>
      <address>
        <city>Wilmington</city>
        <state>Delaware</state>
        <zip>19803</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emi Caywood, MD</last_name>
      <phone>302-651-5500</phone>
      <email>Emi.caywood@nemours.org</email>
    </contact>
    <investigator>
      <last_name>Emy Caywood, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's National Medical Center</name>
      <address>
        <city>Washington, D.C.</city>
        <state>District of Columbia</state>
        <zip>20010-2970</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Blachy DÃ¡vila DÃ¡vila SaldaÃ±a, MD</last_name>
      <phone>(202)476-4561</phone>
      <email>Bjdavilas1@childrensnational.org</email>
    </contact>
    <investigator>
      <last_name>Blachy DÃ¡vila SaldaÃ±a, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>All Children's Hospital, St. Petersburg FL</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Benjamin Oshrine, MD</last_name>
      <phone>727-767-4176</phone>
      <email>Boshrin1@jhmi.edu</email>
    </contact>
    <investigator>
      <last_name>Benjamin Oshrine, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Healthcare of Atlanta/Emory University School of Medicine</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elizabeth Stenger, MD</last_name>
      <phone>404-785-1272</phone>
      <email>Elizabeth.Stenger@choa.org</email>
    </contact>
    <investigator>
      <last_name>Elizabeth Stenger, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ann &amp; Robert H. Lurie Children's Hospital of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60614</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Morris Kletzel, MD</last_name>
      <phone>773-880-4598</phone>
      <email>MKletzel16@northwestern.edu</email>
    </contact>
    <investigator>
      <last_name>Morris Kletzel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital/Louisiana State University Health Sciences Center</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70118</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lolie Yu, MD</last_name>
      <phone>504-896-9740</phone>
      <email>lyu@lsuhsc.edu</email>
    </contact>
    <investigator>
      <last_name>Lolie Yu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NIH Clinical Center Genetic Immunotherapy Section</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Harry Malech, MD</last_name>
      <phone>301-480-6916</phone>
      <email>hmalech@mail.nih.gov</email>
    </contact>
    <investigator>
      <last_name>Harry Malech, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Boston</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sung-Yun Pai, MD</last_name>
      <phone>617-919-2508</phone>
      <email>sung-yun.pai@childrens.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Sung-Yun Pai, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Michigan Health System</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark Vander Lugt, MD</last_name>
      <phone>734-936-9814</phone>
      <email>marvande@med.umich.edu</email>
    </contact>
    <investigator>
      <last_name>Mark Vander Lugt, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Minnesota Medical Center</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angie Smith, MD</last_name>
      <phone>612-626-2778</phone>
      <email>smith719@umn.edu</email>
    </contact>
    <investigator>
      <last_name>Angie Smith, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Hospital</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Richard Bram, MD</last_name>
      <phone>507-284-2695</phone>
      <email>Bramr@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Richard Bram, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cardinal Glennon Children's Medical Center</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wendy Sanders, RN</last_name>
      <phone>314-268-2700</phone>
      <phone_ext>3513</phone_ext>
      <email>Wendy_Sanders@ssmhc.com</email>
    </contact>
    <investigator>
      <last_name>Alan Knutsen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University St Louis Children's Hospital</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shalini Shenoy, MD</last_name>
      <phone>314-454-6018</phone>
      <email>shenoy@wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Shalini Shenoy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alfred Gillio, MD</last_name>
      <phone>201-996-5645</phone>
      <email>AGillio@HackensackUMC.org</email>
    </contact>
    <investigator>
      <last_name>Alfred Gillio, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Monica Bhatia, MD</last_name>
      <phone>212-305-9138</phone>
      <email>mb2476@columbia.edu</email>
    </contact>
    <investigator>
      <last_name>Monica Bhatia, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Richard J O'Reilly</last_name>
      <phone>212-639-5957</phone>
      <email>oreillyr@mskc.org</email>
    </contact>
    <investigator>
      <last_name>Richard J O'Reilly, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Rochester Medical Center/ Golisano Children's Hospital</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeffrey Andolina, MD</last_name>
      <phone>585-276-3229</phone>
      <email>Jeffrey_andolina@urmc.rochester.edu</email>
    </contact>
    <investigator>
      <last_name>Jeffrey Andolina, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>New York Medical College, Maria Fareri Children's Hospital</name>
      <address>
        <city>Valhalla</city>
        <state>New York</state>
        <zip>10595</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Allyson Flower, MD</last_name>
      <phone>914-493-7997</phone>
      <email>Allyson_flower@nymc.edu</email>
    </contact>
    <investigator>
      <last_name>Allyson Flower, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke University</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rebecca Buckley, MD</last_name>
      <phone>919-684-2922</phone>
      <email>buckl003@mc.duke.edu</email>
    </contact>
    <investigator>
      <last_name>Rebecca Buckley, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sharat Chandra, MD</last_name>
      <phone>513-636-5917</phone>
      <email>Sharat.Chandra@cchmc.org</email>
    </contact>
    <investigator>
      <last_name>Sharat Chandra, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rainbow Babies/ University Hospitals Case Medical Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jignesh Dalal, MD</last_name>
      <phone>216-844-3345</phone>
      <email>Jignesh.Dalal@UHhospitals.org</email>
    </contact>
    <investigator>
      <last_name>Jignesh Dalal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nationwide Children's Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rolla Abu-arja, MD</last_name>
      <phone>614-722-3582</phone>
      <email>Rolla.abu-arja@nationwidechildrens.org</email>
    </contact>
    <investigator>
      <last_name>Rolla Abu-Arja, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oregon Health and Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239-3098</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Evan Shereck, MD</last_name>
      <phone>503-494-0829</phone>
      <email>Shereck@ohsu.edu</email>
    </contact>
    <investigator>
      <last_name>Evan Shereck, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Heimall, MD</last_name>
      <phone>215-590-2549</phone>
      <email>heimallj@email.chop.edu</email>
    </contact>
    <investigator>
      <last_name>Jennifer Heimall, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Pittsburgh of UPMC</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jessie Barnum, MD</last_name>
      <phone>412-692-7035</phone>
      <email>jessie.barnum@chp.edu</email>
    </contact>
    <investigator>
      <last_name>Jessie Barnum, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Jude Children's Research Hospital</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ewelina Mamcarz, MD</last_name>
      <phone>901-595-8343</phone>
      <email>ewelina.mamcarz@stjude.org</email>
    </contact>
    <investigator>
      <last_name>Ewelina Mamcarz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern Medical Center/Children's of Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390-9263</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Victor Aquino, MD</last_name>
      <phone>214-648-8800</phone>
      <email>victor.aquino@utsouthwestern.edu</email>
    </contact>
    <investigator>
      <last_name>Victor Aquino, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Children's Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-2399</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chivon McMullen-Jackson, RN, BSN</last_name>
      <phone>832-824-1339</phone>
      <email>cdmcmull@texaschildrens.org</email>
    </contact>
    <investigator>
      <last_name>William Shearer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Methodist Children's Hospital of South Texas/Texas Transplant Institute</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Troy Quigg, MD</last_name>
      <phone>210-575-7348</phone>
      <email>Troy.Quigg@MHShealth.com</email>
    </contact>
    <investigator>
      <last_name>Troy Quigg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Primary Children's Medical Center/University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84113</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Shyr, MD</last_name>
      <phone>801-662-4736</phone>
      <email>David.Shyr@hsc.utah.edu</email>
    </contact>
    <investigator>
      <last_name>David Shyr, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seattle Children's Research Institute</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98101</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lauri M Burroughs, MD</last_name>
      <phone>206-667-2396</phone>
      <email>lburroug@fhcrc.org</email>
    </contact>
    <investigator>
      <last_name>Lauri M Burroughs, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin/ American Family Children's Hospital</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53705-2275</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kenneth DeSantes, MD</last_name>
      <phone>608-263-8563</phone>
      <email>kbdesantes@pediatrics.wisc.edu</email>
    </contact>
    <investigator>
      <last_name>Kenneth DeSantes</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226-4874</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Monica S Thakar, MD</last_name>
      <phone>414-266-6848</phone>
      <email>mthakar@mcw.edu</email>
    </contact>
    <investigator>
      <last_name>Monica S Thakar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Alberta Children's Hospital</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T3B 6A8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nicola Wright, MD</last_name>
      <phone>403-955-3035</phone>
      <email>Nicola.Wright@albertahealthservices.ca</email>
    </contact>
    <investigator>
      <last_name>Nicola Wright, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>British Columbia Children's Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6H 3V4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeffrey Davis, MD</last_name>
      <phone>604-875-3577</phone>
      <email>jdavis@cw.bc.ca</email>
    </contact>
    <investigator>
      <last_name>Jeffrey Davis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cancer Care Manitoba</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3E 0V9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Geoff Cuvelier, MD</last_name>
      <phone>204-787-8689</phone>
      <email>geoff.cuvelier@cancercare.mb.ca</email>
    </contact>
    <investigator>
      <last_name>Geoff Cuvelier, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Hospital for Sick Children</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1XB</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eyal Grunebaum, MD</last_name>
      <phone>416-813-7654</phone>
      <email>Eyal.Grunebaum@sickkids.ca</email>
    </contact>
    <investigator>
      <last_name>Eyal Grunebaum, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU St. Justine</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3T 1C5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elie Haddad, MD</last_name>
      <phone>514-345-4931</phone>
      <phone_ext>6217</phone_ext>
      <email>elie.haddad@umontreal.ca</email>
    </contact>
    <investigator>
      <last_name>Elie Haddad, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.niaid.nih.gov/</url>
    <description>National Institute of Allergy and Infectious Diseases (NIAID)</description>
  </link>
  <link>
    <url>http://rarediseasesnetwork.epi.usf.edu/PIDTC/</url>
    <description>Primary Immune Deficiency Treatment Consortium (PIDTC)</description>
  </link>
  <reference>
    <citation>Griffith LM, Cowan MJ, Kohn DB, Notarangelo LD, Puck JM, Schultz KR, Buckley RH, Eapen M, Kamani NR, O'Reilly RJ, Parkman R, Roifman CM, Sullivan KE, Filipovich AH, Fleisher TA, Shearer WT. Allogeneic hematopoietic cell transplantation for primary immune deficiency diseases: current status and critical needs. J Allergy Clin Immunol. 2008 Dec;122(6):1087-96. doi: 10.1016/j.jaci.2008.09.045. Epub 2008 Nov 6.</citation>
    <PMID>18992926</PMID>
  </reference>
  <results_reference>
    <citation>Dvorak CC, Cowan MJ, Logan BR, Notarangelo LD, Griffith LM, Puck JM, Kohn DB, Shearer WT, O'Reilly RJ, Fleisher TA, Pai SY, Hanson IC, Pulsipher MA, Fuleihan R, Filipovich A, Goldman F, Kapoor N, Small T, Smith A, Chan KW, Cuvelier G, Heimall J, Knutsen A, Loechelt B, Moore T, Buckley RH. The natural history of children with severe combined immunodeficiency: baseline features of the first fifty patients of the primary immune deficiency treatment consortium prospective study 6901. J Clin Immunol. 2013 Oct;33(7):1156-64. doi: 10.1007/s10875-013-9917-y. Epub 2013 Jul 2.</citation>
    <PMID>23818196</PMID>
  </results_reference>
  <results_reference>
    <citation>Shearer WT, Dunn E, Notarangelo LD, Dvorak CC, Puck JM, Logan BR, Griffith LM, Kohn DB, O'Reilly RJ, Fleisher TA, Pai SY, Martinez CA, Buckley RH, Cowan MJ. Establishing diagnostic criteria for severe combined immunodeficiency disease (SCID), leaky SCID, and Omenn syndrome: the Primary Immune Deficiency Treatment Consortium experience. J Allergy Clin Immunol. 2014 Apr;133(4):1092-8. doi: 10.1016/j.jaci.2013.09.044. Epub 2013 Nov 28.</citation>
    <PMID>24290292</PMID>
  </results_reference>
  <results_reference>
    <citation>Haddad E, Allakhverdi Z, Griffith LM, Cowan MJ, Notarangelo LD. Survey on retransplantation criteria for patients with severe combined immunodeficiency. J Allergy Clin Immunol. 2014 Feb;133(2):597-9. doi: 10.1016/j.jaci.2013.10.022. Epub 2013 Dec 10.</citation>
    <PMID>24331379</PMID>
  </results_reference>
  <results_reference>
    <citation>Griffith LM, Cowan MJ, Notarangelo LD, Kohn DB, Puck JM, Pai SY, Ballard B, Bauer SC, Bleesing JJ, Boyle M, Brower A, Buckley RH, van der Burg M, Burroughs LM, Candotti F, Cant AJ, Chatila T, Cunningham-Rundles C, Dinauer MC, Dvorak CC, Filipovich AH, Fleisher TA, Bobby Gaspar H, Gungor T, Haddad E, Hovermale E, Huang F, Hurley A, Hurley M, Iyengar S, Kang EM, Logan BR, Long-Boyle JR, Malech HL, McGhee SA, Modell F, Modell V, Ochs HD, O'Reilly RJ, Parkman R, Rawlings DJ, Routes JM, Shearer WT, Small TN, Smith H, Sullivan KE, Szabolcs P, Thrasher A, Torgerson TR, Veys P, Weinberg K, Zuniga-Pflucker JC; workshop participants. Primary Immune Deficiency Treatment Consortium (PIDTC) report. J Allergy Clin Immunol. 2014 Feb;133(2):335-47. doi: 10.1016/j.jaci.2013.07.052. Epub 2013 Oct 15.</citation>
    <PMID>24139498</PMID>
  </results_reference>
  <results_reference>
    <citation>Griffith LM, Cowan MJ, Notarangelo LD, Kohn DB, Puck JM, Shearer WT, Burroughs LM, Torgerson TR, Decaluwe H, Haddad E; workshop participants. Primary Immune Deficiency Treatment Consortium (PIDTC) update. J Allergy Clin Immunol. 2016 Aug;138(2):375-85. doi: 10.1016/j.jaci.2016.01.051. Epub 2016 Apr 22. Review.</citation>
    <PMID>27262745</PMID>
  </results_reference>
  <results_reference>
    <citation>Pai SY, Logan BR, Griffith LM, Buckley RH, Parrott RE, Dvorak CC, Kapoor N, Hanson IC, Filipovich AH, Jyonouchi S, Sullivan KE, Small TN, Burroughs L, Skoda-Smith S, Haight AE, Grizzle A, Pulsipher MA, Chan KW, Fuleihan RL, Haddad E, Loechelt B, Aquino VM, Gillio A, Davis J, Knutsen A, Smith AR, Moore TB, Schroeder ML, Goldman FD, Connelly JA, Porteus MH, Xiang Q, Shearer WT, Fleisher TA, Kohn DB, Puck JM, Notarangelo LD, Cowan MJ, O'Reilly RJ. Transplantation outcomes for severe combined immunodeficiency, 2000-2009. N Engl J Med. 2014 Jul 31;371(5):434-46. doi: 10.1056/NEJMoa1401177.</citation>
    <PMID>25075835</PMID>
  </results_reference>
  <results_reference>
    <citation>Griffith LM, Cowan MJ, Notarangelo LD, Puck JM, Buckley RH, Candotti F, Conley ME, Fleisher TA, Gaspar HB, Kohn DB, Ochs HD, O'Reilly RJ, Rizzo JD, Roifman CM, Small TN, Shearer WT; Workshop Participants. Improving cellular therapy for primary immune deficiency diseases: recognition, diagnosis, and management. J Allergy Clin Immunol. 2009 Dec;124(6):1152-60.e12. doi: 10.1016/j.jaci.2009.10.022.</citation>
    <PMID>20004776</PMID>
  </results_reference>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 20, 2010</study_first_submitted>
  <study_first_submitted_qc>August 20, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 23, 2010</study_first_posted>
  <last_update_submitted>October 10, 2017</last_update_submitted>
  <last_update_submitted_qc>October 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>SCID disorders</keyword>
  <keyword>natural history study</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Severe Combined Immunodeficiency</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

